Prevalence and risk factors for colonisation with extended spectrum beta-lactamase producing enterobacteriacae vis-à-vis usage of antimicrobials

Indian Journal of Medical Microbiology
J B Sarma, G U Ahmed

Abstract

A point prevalence study was carried out in a teaching hospital in Assam to determine the prevalence, sensitivity profile and risk factors for acquisition of extended spectrum beta-lactamase (ESBL) producing enterobacteriacae vis-upsilon-vis amount and pattern of antibiotic use. ESBL was detected by double disc synergy method. Defined daily dose and bed-days were calculated. Colonisation rate of ESBL producing enterobacteriacae ranged from 14% (n=73) in medicine to the highest 41% (n=29) in orthopaedic with an intermediate 23% (n=80) in surgery. Presence of ESBL was found to be strongly associated with resistance to specific classes of antimicrobials. Exposure to cefotaxime and gentamicin, and surgery were risk factors for acquiring ESBL producing enterobacteriacae. Non-ESBL producing community isolates were found to be considerably more sensitive to different antibiotics with no resistance detected to trimethoprim, co-trimoxazole, ciprofloxacin and aminoglycosides. The study confirms the role of certain 'high risk' antimicrobials in acquisition of ESBL producing Enterobacteriaceae and shows that periodic cohort studies could be an effective strategy in surveillance of antimicrobial resistance in hospitals of resource poor coun...Continue Reading

References

Jan 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A A Medeiros
Feb 18, 1999·JAMA : the Journal of the American Medical Association·J WienerR A Weinstein
Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A AsensioR Cantón
Apr 3, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E LautenbachN O Fishman
Apr 11, 2001·Emerging Infectious Diseases·L K Archibald, L B Reller
Jun 23, 2001·The Journal of Antimicrobial Chemotherapy·D M Livermore, D F Brown
Jun 23, 2001·The Journal of Antimicrobial Chemotherapy·D M LivermoreK P Shannon
Aug 2, 2001·The Journal of Antimicrobial Chemotherapy·J M Andrews, R Wise
Mar 29, 2002·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Matthieu EveillardFrançois Eb
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·R Bonnet
Jun 25, 2004·The Journal of Antimicrobial Chemotherapy·Spyros PournarasAntonios N Maniatis
Oct 15, 2005·Clinical Microbiology Reviews·David L Paterson, Robert A Bonomo

❮ Previous
Next ❯

Citations

Sep 3, 2011·Journal of Global Infectious Diseases·Olusolabomi J IdowuGbolahan O Babalola
Feb 24, 2011·Expert Review of Anti-infective Therapy·Timothy R Walsh, Mark A Toleman
Apr 5, 2014·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Xiaoli CaoKui Zhang
Aug 16, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Dilip MathaiLalitha Mukkai Kesavan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.